throbber
US007608261B2
`
`(12) Ulllted States Patent
`Fur?ne et a].
`
`(10) Patent N0.:
`(45) Date of Patent:
`
`US 7,608,261 B2
`*Oct. 27, 2009
`
`(54) VEGF ANTAGONIST FORMULATIONS
`SUITABLE FOR INTRAVITREAL
`ADMINISTRATION
`
`(75) Inventors: Eric Fur?ne, Concord, MA (US);
`Daniel Dix, LaGrangeVille, NY (US);
`Kenneth S. Graham, Pleasant Valley,
`NY (US); Kelly Frye, Pomona, NY (US)
`
`(73) Assignee: Regeneron Pharmacuticals, Inc.,
`Tan-ytOWn’ NY (Us)
`
`( * ) Notice:
`
`Subject‘ to any disclaimer, the term of this
`patent 1s extended or adjusted under 35
`U.S.C. 154(b) by 47 days.
`
`This patent is subject to a terminal dis-
`Clalmer'
`
`_
`(21) Appl' NO" 11/818’463
`(22) Filed:
`Jun. 14, 2007
`
`(56)
`
`(52) US. Cl. ................... .. 424/1341; 424/1921; 514/2;
`514/12; 530/3 50; 536/234
`(58) Field of Classi?cation Search ..................... .. None
`See application ?le for complete search history.
`_
`References Clted
`U S PATENT DOCUMENTS
`'
`'
`8/2000 Davis-Smyth et a1.
`6,100,071 A
`5/2005 DaVis-Smyth et a1.
`6,897,294 B2
`2005/0281831 A1 12/2005 DaVis-Smyth et a1.
`2006/0217311 A1
`9/2006 Dix et a1.
`FOREIGN PATENT DOCUMENTS
`
`1/2005
`W0 WO 2005/000895 A
`5/2006
`W0 WO 2006/047325 A
`W0 WO 2006/104852 A 10/2006
`Primary ExamineriChristine J Saoud
`Assistant Examineril on M Lockard
`(74) Attorney, Agent, or FirmiValeta Gregg, Esq.; Tor
`Smeland, Esq
`
`(65)
`
`Prior Publication Data
`
`(57)
`
`ABSTRACT
`
`US 2007/0293432 A1
`
`Dec. 20, 2007
`
`Related U-s- Application Data
`(60) Provisional application NO 60/814 484 ?led on Jun
`16 2006
`i
`’
`’
`i
`’
`'
`(51) Int. Cl.
`A61K 38/18
`C07K 14/71
`
`(2006.01)
`(2006.01)
`
`Ophthalmic formulations of a Vascular endothelial growth
`factor (V EGF)-speci?c fusion protein antagonist are pro
`Vided suitable for intravitreal administration to the eye. The
`ophthalmic formulations include a stable liquid formulation
`and a lyophiliZable formulation. Preferably, the protein
`antagonist has the amino acid sequence shoWn in SEQ ID
`N014
`
`17 Claims, No Drawings
`
`Mylan Exhibit 1157
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`

`

`US 7,608,261 B2
`
`1
`VEGF ANTAGONIST FORMULATIONS
`SUITABLE FOR INTRAVITREAL
`ADMINISTRATION
`
`CROSS-REFERENCE TO RELATED
`APPLICATIONS
`
`This application claims the bene?t under 35 USC § 119(e)
`of US. Provisional 60/814,484 ?led 16 Jun. 2006, Which
`application is herein speci?cally incorporated by reference in
`its entirety.
`
`BACKGROUND OF INVENTION
`
`1. Field of the Invention
`The present invention is directed to pharmaceutical formu
`lations suitable for intravitreal administration comprising
`agents capable of inhibiting vascular endothelial groWth fac
`tor (V EGF), and to methods for making and using such for
`mulations. The invention includes liquid pharmaceutical for
`mulations having increased stability, as Well as formulations
`that may be lyophiliZe and reconstituted for intravitreal
`administration.
`2. Statement of Related Art
`Vascular endothelial groWth factor (VEGF) expression is
`nearly ubiquitous in human cancer, consistent With its role as
`a key mediator of tumor neoangio genesis. Blockade of VEGF
`function, by binding to the molecule or its VEGFR-2 receptor,
`inhibits groWth of implanted tumor cells in multiple different
`xenograft models (see, for example, Gerber et al. (2000)
`Cancer Res. 60: 6253-6258). A soluble VEGF-speci?c fusion
`protein antagonist, termed a “VEGF trap” has been described
`(Kim et al. (2002) Proc. Natl. Acad. Sci. USA 99: 1 1399-404;
`Holash et al. (2002) Proc. Natl. Acad. Sci. USA 99:11393-8),
`Which applications are speci?cally incorporated by reference
`in their entirety.
`Ophthalmic formulations are knoWn, see for example, US.
`Pat. Nos. 7,033,604 and 6,777,429. An ophthalmic formula
`tion of aVEGF antibody is described in US. Pat. No. 6,676,
`941 .
`
`LyophiliZation (freeZe drying under controlled conditions)
`is commonly used for long-term storage of proteins. The
`lyophiliZed protein is substantially resistant to degradation,
`aggregation, oxidation, and other degenerative processes
`While in the freeZe-dried state (see, for example, US. Pat. No.
`6,436,897).
`
`BRIEF SUMMARY OF THE INVENTION
`
`Stable formulations of a VEGF-speci?c fusion protein
`antagonist are provided. Pharmaceutically acceptable formu
`lations are provided that comprise a VEGF “trap” antagonist
`With a pharmaceutically acceptable carrier. In speci?c
`embodiments, liquid and lyophiliZed formulations are pro
`vided.
`In a ?rst aspect, a stable liquid ophthalmic formulation of a
`VEGF-speci?c fusion protein antagonist is provided, com
`prising a fusion protein that comprises a receptor component
`consisting essentially of an immunoglobulin-like (Ig) domain
`2 of a ?rst VEGF receptor and Ig domain 3 of a second VEGF
`receptor, and a multimeriZing component (also termed a
`“VEGF trap”). In a speci?c embodiment of the VEGF-spe
`ci?c fusion protein antagonist, the ?rst VEGF receptor is Fltl
`and the second VEGF receptor is Flkl or Flt4. In a more
`speci?c embodiment the fusion protein has the amino acid
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`2
`sequence of SEQ ID NO:2 or SEQ ID NO:4. Preferably, the
`VEGF antagonist is a dimer comprising tWo fusion proteins
`of SEQ ID NO:4.
`In one aspect, a stable liquid ophthalmic formulation is
`provided that comprises 1-100 mg/ml VEGF-speci?c fusion
`protein antagonist, 0.01-5% of one or more organic co-sol
`vent(s), 30-150 mM of one or more tonicity agent(s), 5-40
`mM of a buffering agent, and optionally, 1.0-7.5% of a sta
`biliZing agent, pH betWeen about 5.8-7.0.
`In one or more speci?c embodiments, the organic co-sol
`vent may be polysorbate, for example, polysorbate 20 or
`polysorbate 80, polyethylene glycol (PEG), for example,
`PEG 3350, or propylene glycol, or a combination thereof; the
`tonicity agent may be, for example, sodium chloride or potas
`sium chloride; the stabiliZing agent may be sucrose, sorbitol,
`glycerol, trehalose, or mannitol; and the buffering agent may
`be, for example, phosphate buffer. In a speci?c embodiment,
`the phosphate buffer is a sodium phosphate buffer.
`In various embodiments, the organic co-solvent is polysor
`bate and/or PEG, the stabiliZing agent is sucrose, the buffer
`ing agent is phosphate buffer, and the tonicity agent is sodium
`chloride.
`More speci?cally, the stable liquid ophthalmic formulation
`comprises about 40-50 mg/ml of the VEGF antagonist (SEQ
`ID NO:4), about 10 mM phosphate buffer, 0.01 -3% polysor
`bate and/or PEG, 40-135 mM sodium chloride, and option
`ally 5.0% sucrose, pH about 6.2-6.3.
`In a speci?c preferred embodiment, the stable liquid oph
`thalmic formulation comprises about 50 mg/ml of the VEGF
`antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer,
`50 mM sodium chloride, 0.1% polysorbate, and 5% sucrose,
`pH about 62-63.
`In a speci?c preferred embodiment, the stable liquid oph
`thalmic formulation comprises about 50 mg/ml of the VEGF
`antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer,
`50 mM sodium chloride, 3% PEG, and 5% sucrose, pH about
`62-63.
`In a speci?c preferred embodiment, the stable liquid oph
`thalmic formulation comprises about 40 mg/ml of the VEGF
`antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer,
`40 mM sodium chloride, 0.03% polysorbate, and 5% sucrose,
`pH about 62-63.
`In a speci?c preferred embodiment, the stable liquid oph
`thalmic formulation comprises about 40 mg/ml of the VEGF
`antagonist (SEQ ID NO:4), 10 mM sodium phosphate buffer,
`135 mM sodium chloride, and 0.03% polysorbate, pH about
`62-63.
`In another aspect, a stable liquid ophthalmic formulation is
`provided that comprises 1-100 mg/ml VEGF-speci?c fusion
`protein antagonist; 0.01-5% of one or more organic co-sol
`vent(s); 5-40 mM of a buffering agent; and optionally 30-150
`mM of one or more tonicity agent(s) and/or 1.0-7.5% of a
`stabiliZing agent; having a pH betWeen about 58-70.
`In various embodiments, the VEGF antagonist (SEQ ID
`NO:4) is present at a concentration of about 10 to about 80
`mg/ml. In various embodiments, the VEGF antagonist (SEQ
`ID NO:4) is present at a concentration of about 10, about 20,
`about 30, about 40, about 50, about 60, about 70, or about 80
`mg/ml. In a preferred embodiment, the VEGF antagonist
`(SEQ ID NO:4) is present at a concentration of about 40
`mg/ml.
`In another embodiment, the stabiliZing agent is selected
`from one or more of sucrose, sorbitol, glycerol, trehalose, and
`mannitol.
`In another embodiment, the organic co-solvent is selected
`from one or more of polysorbate, for example, polysorbate 20
`
`Mylan Exhibit 1157
`Mylan v. Regeneron, IPR2021-00881
`Page 2
`
`

`

`US 7,608,261 B2
`
`20
`
`25
`
`3
`or polysorbate 80, polyethylene glycol (PEG), for example,
`PEG 3350, and propylene glycol.
`In another embodiment, the buffer is a phosphate buffer, for
`example, sodium phosphate.
`In another embodiment, the tonicity agent is a salt, for
`example, sodium chloride.
`In one embodiment, the stable liquid ophthalmic formula
`tion comprises 10 mM sodium phosphate buffer, about 0.03 to
`about 0.1% polysorbate and/or about 3% PEG or propylene
`glycol, about 40 mM sodium chloride, and about 5% sucrose.
`In a speci?c embodiment, the stable liquid ophthalmic for
`mulation comprises 10 mM sodium phosphate buffer, about
`0.03% polysorbate, about 40 mM sodium chloride, and about
`5% sucrose. In another speci?c embodiment, the pH of the
`formulation is about 6.2 to about 6.3. In another speci?c
`embodiment, the pH is achieved by mixing mono- and dibasic
`sodium phosphate to the desired pH Without acid/base titra
`tion.
`In a speci?c embodiment, the stable liquid ophthalmic
`formulation consists essentially of a VEGF antagonist (SEQ
`ID N014) at 40 mg/ml, 10 mM sodium phosphate buffer,
`polysorbate at 0.03%, sodium chloride at 40 mM, and sucrose
`at 5%, pH 6.2-6.3.
`In another aspect, a stable liquid ophthalmic formulation is
`provided that comprises about 10 to about 80 mg/ml VEGF
`antagonist, about 10 mM sodium phosphate buffer, about
`0.03% polysorbate, and about 135 mM sodium chloride, pH
`6.2 to 6.3.
`In various embodiments, the VEGF antagonist (SEQ ID
`N014) is present at a concentration of about 10 to about 80
`mg/ml. In various embodiments, the VEGF antagonist (SEQ
`ID N014) is present at a concentration of about 10, about 20,
`about 30, about 40, about 50, about 60, about 70, or about 80
`mg/ml. In a speci?c embodiment, the VEGF antagonist (SEQ
`ID N014) is present at a concentration of about 40 mg/ml.
`In one embodiment, the stable liquid ophthalmic formula
`tion comprises 40 mg/ml of VEGF antagonist (SEQ ID
`N014), 10 mM sodium phosphate buffer, 0.03% polysorbate,
`and 135 mM sodium chloride at pH 6.2-6.3. In a speci?c
`embodiment, the stable liquid ophthalmic formulation con
`sists essentially of 40 mg/ml of VEGF antagonist (SEQ ID
`N014), 10 mM sodium phosphate buffer, 0.03% polysorbate,
`and 135 mM sodium chloride at pH 6.2-6.3.
`In another aspect, a lyophiliZable formulation of a VEGF
`45
`antagonist is provided, Wherein upon lyophiliZation folloWed
`by reconstitution, a stable liquid ophthalmic formulation as
`described herein is obtained.
`In another aspect, a lyophiliZable formulation of a vascular
`endothelial groWth factor (V EGF)-speci?c fusion protein
`antagonist is provided, comprising 5-50 mg/ml of the VEGF
`antagonist, 5-25 mM buffer, such as phosphate buffer, 0.01 to
`0.15% of one or more of an organic co-solvent, such as
`polysorbate, propylene glycol and/or PEG, and optionally
`1-10% of a stabiliZing agent such as sucrose, sorbitol, treha
`lose, glycerol, or mannitol, pH about 5.8-7.0. In various
`embodiments, the VEGF antagonist (SEQ ID N014) is
`present at about 5, about 10, about 20, about 30, or about 40
`mg/ml. In a speci?c embodiment, the lyophiliZable oph
`thalmic formulation of the invention comprises 20 mg/ml of
`the VEGF antagonist, 10 mM sodium phosphate buffer,
`0.03% polysorbate, 0.1% PEG, and 2.5% sucrose, pH about
`6.2-6.3. In further embodiments, the lyophiliZable formula
`tion further comprises sodium chloride. In a speci?c embodi
`ment, the sodium chloride is present at a concentration of
`about 20 mM. In another speci?c embodiment, the sodium
`chloride is present at a concentration of about 67.5 mM.
`
`4
`In another speci?c embodiment, the lyophiliZable oph
`thalmic formulation of the invention comprises 20 mg/ml of
`the VEGF antagonist, 5 mM sodium phosphate buffer,
`0.015% polysorbate, 20 mM sodium chloride, and 2.5%
`sucrose, pH about 6.2-6.3.
`In another embodiment, the lyophiliZable ophthalmic for
`mulation comprises 5 mg/ml, 10 mg/ml, or 40 mg/ml VEGF
`antagonist, 5 mM sodium phosphate buffer, 0.015% polysor
`bate, 20 mM sodium chloride, and 2.5% sucrose, at pH 6.2
`6.3. In a speci?c embodiment, the lyophiliZable ophthalmic
`formulation consists essentially of 5 mg/ml, 10 mg/ml, or 40
`mg/ml VEGF antagonist (SEQ ID N014), 5 mM sodium
`phosphate buffer, 0.015% polysorbate, 20 mM sodium chlo
`ride, and 2.5% sucrose, at pH 6.2-6.3.
`In another speci?c embodiment, the lyophiliZable oph
`thalmic formulation comprises 20 mg/ml of the VEGF
`antagonist, 5 mM sodium phosphate buffer, 0.015% polysor
`bate, and 67.5 mM sodium chloride, pH about 6.2-6.3. In a
`more speci?c embodiment, the lyophiliZable ophthalmic for
`mulation consists essentially of 20 mg/ml of the VEGF
`antagonist (SEQ ID N014), 5 mM sodium phosphate buffer,
`0.015% polysorbate, and 67.5 mM sodium chloride, pH 6.2
`6.3.
`In another speci?c embodiment, the lyophiliZable oph
`thalmic formulation comprises 5 mg/ml, 10 mg/ml, or 40
`mg/ml VEGF antagonist, 5 mM sodium phosphate buffer,
`0.015% polysorbate, and 67.5 mM sodium chloride, pH about
`6.2-6.3. In a more speci?c embodiment, the lyophiliZable
`ophthalmic formulation consists essentially of 5 mg/ml, 10
`mg/ml, or 40 mg/mlVEGF antagonist (SEQ ID N014), 5 mM
`sodium phosphate buffer, 0.015% polysorbate, and 67.5 mM
`sodium chloride, pH about 6.2-6.3.
`Generally, the reconstituted formulation is about 2 times
`the concentration of the pre-lyophiliZed formulation, e.g., a
`20 mg fusion protein/ml pre-lyophiliZed formulation is
`reconstituted to a ?nal formulation of 40 mg fusion protein/
`ml.
`Generally, the lyophiliZed formulation is reconstituted
`With sterile Water suitable for injection. In one embodiment,
`the reconstitution liquid is bacteriostatic Water.
`In another aspect, the invention features a method of pro
`ducing a lyophiliZed formulation of a VEGF-speci?c fusion
`protein antagonist, comprising subjecting the lyophiliZable
`formulation of the invention to lyophiliZation to generate a
`lyophiliZed formulation. The lyophiliZed formulation may be
`lyophiliZed by any method knoWn in the art for lyophiliZing a
`liquid.
`In another related aspect, the invention features a method
`of producing a reconstituted lyophiliZed formulation of a
`VEGF antagonist, comprising reconstituting the lyophiliZed
`formulation of the invention to a reconstituted formulation. In
`one embodiment, the reconstituted formulation is tWice the
`concentration of the pre-lyophiliZed formulation, e.g., the
`method of the invention comprises: (a) producing a pre-lyo
`philiZed formulation of a VEGF-speci?c fusion protein
`antagonist, (b) subjecting the pre-lyophiliZed formulation of
`step (a) to lyophiliZation; and (c) reconstituting the lyo
`philiZed formulation of step (b).
`The invention further features ophthalmic formulations
`provided in a pre-?lled syringe or vial, particularly suitable
`for intravitreal administration.
`
`30
`
`35
`
`40
`
`50
`
`55
`
`60
`
`65
`
`Mylan Exhibit 1157
`Mylan v. Regeneron, IPR2021-00881
`Page 3
`
`

`

`US 7,608,261 B2
`
`5
`Other objects and advantages Will become apparent from a
`review of the ensuing detailed description.
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`The present invention is not limited to particular methods,
`and experimental conditions described, as such methods and
`conditions may vary. It is also to be understood that the
`terminology used herein is for the purpose of describing
`particular embodiments only, and is not intended to be limit
`ing unless indicated, since the scope of the present invention
`Will be limited only by the appended claims.
`Unless stated otherWise, all technical and scienti?c terms
`and phrases used herein have the same meaning as commonly
`understood by one of ordinary skill in the art to Which the
`invention belongs. Although any methods and materials simi
`lar or equivalent to those described herein can be used in the
`practice or testing of the present invention, the preferred
`methods and materials are noW described. All publications
`mentioned herein are incorporated herein by reference.
`General Description
`Safe handling and administration of formulations compris
`ing proteins represent signi?cant challenges to pharmaceuti
`cal formulators. Proteins possess unique chemical and physi
`cal properties that present stability problems: a variety of
`degradation pathWays exist for proteins, implicating both
`chemical and physical instability. Chemical instability
`includes deamination, aggregation, clipping of the peptide
`backbone, and oxidation of methionine residues. Physical
`instability encompasses many phenomena, including, for
`example, aggregation and/ or precipitation.
`Chemical and physical stability can be promoted by
`removing Water from the protein. LyophiliZation (freeZe-dry
`ing under controlled conditions) is commonly used for long
`term storage of proteins. The lyophiliZed protein is substan
`tially resistant to degradation, aggregation, oxidation, and
`other degenerative processes While in the freeZe-dried state.
`The lyophiliZed protein may be reconstituted With Water
`optionally containing a bacteriostatic preservative (e.g., ben
`Zyl alcohol) prior to administration.
`
`DEFINITIONS
`
`The term “carrier” includes a diluent, adjuvant, excipient,
`or vehicle With Which a composition is administered. Carriers
`can include sterile liquids, such as, for example, Water and
`oils, including oils of petroleum, animal, vegetable or syn
`thetic origin, such as, for example, peanut oil, soybean oil,
`mineral oil, sesame oil and the like.
`The term “excipient” includes a non-therapeutic agent
`added to a pharmaceutical composition to provide a desired
`consistency or stabiliZing effect. Suitable pharmaceutical
`excipients include, for example, starch, glucose, lactose,
`sucrose, gelatin, malt, rice, ?our, chalk, silica gel, sodium
`stearate, glycerol monostearate, talc, sodium chloride, dried
`skim milk, glycerol, propylene, glycol, Water, ethanol and the
`like.
`The term “lyophiliZed” or “freeze-dried” includes a state of
`a substance that has been subjected to a drying procedure such
`as lyophiliZation, Where at least 90% of moisture has been
`removed.
`VEGF Antagonists
`AVEGF antagonist is a compound capable of blocking or
`inhibiting the biological action of vascular endothelial groWth
`factor (V EGF), and includes fusion proteins capable of trap
`ping VEGF. In a preferred embodiment, the VEGF antagonist
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`6
`is the fusion protein of SEQ ID NO:2 or 4; more preferably,
`SEQ ID NO:4. In speci?c embodiments, the VEGF antago
`nist is expressed in a mammalian cell line such as a CHO cell
`and may be modi?ed post-translationally. In a speci?c
`embodiment, the fusion protein comprises amino acids
`27-457 of SEQ ID NO4 and is glycosylated at Asn residues
`62, 94, 149, 222 and 308. Preferably, the VEGF antagonist is
`a dimer composed of tWo fusion proteins of SEQ ID NO:4.
`The VEGF antagonist of the methods and formulations of
`the invention can be prepared by any suitable method knoWn
`in the art, or that comes to be knoWn. The VEGF antagonist is
`preferably substantially free of protein contaminants at the
`time it is used to prepare the pharmaceutically acceptable
`formulation. By “substantially free of protein contaminants”
`is meant, preferably, that at least 90% of the Weight of protein
`of the VEGF-speci?c fusion protein antagonist preparation
`used for making a formulation is VEGF fusion protein
`antagonist protein, more preferably at least 95%, most pref
`erably at least 99%. The fusion protein is preferably substan
`tially free of aggregates. “Substantially free of aggregates”
`means that at least 90% of the Weight of fusion protein is not
`present in an aggregate at the time the fusion protein is used to
`prepare the pharmaceutically effective formulation. Unless
`stated otherWise, the phosphates employed are sodium phos
`phates and a desired buffering pH is achieved by mixing
`appropriate amounts of mono- and dibasic sodium phosphate.
`Stable Liquid Ophthalmic Formulations
`In one aspect, the invention provides a stable pharmaceu
`tically acceptable formulation comprising a VEGF antago
`nist, Wherein the formulation is a liquid formulation suitable
`for ophthalmic use. Preferably, the liquid formulation com
`prises a pharmaceutically effective amount of the VEGF
`antagonist. The formulation can also comprise one or more
`pharmaceutically acceptable carriers, buffers, tonicity agents,
`stabiliZers, and/ or excipients. An example of a pharmaceuti
`cally acceptable liquid formulation comprises a VEGF
`antagonist in a pharmaceutically effective amount, a buffer,
`an organic co-solvent such as polysorbate, a tonicity agent
`such as NaCl, and optionally, a stabiliZer such as sucrose or
`trehalose.
`Stability is determined in a number of Ways at speci?ed
`time points, including determination of pH, visual inspection
`of color and appearance, determination of total protein con
`tent by methods knoWn in the art, e. g., UV spectroscopy, and
`purity is determined by, for example, SDS-PAGE, siZe-exclu
`sion HPLC, bioassay determination of activity, isoelectric
`focusing, and isoaspartate quanti?cation. In one example of a
`bioassay useful for determining VEGF antagonist activity, a
`BAF/3 VEGFRl/EPOR cell line is used to determine
`VEGFl65 binding by the VEGF antagonist of the invention.
`Liquid formulations can be stored in an oxygen-deprived
`environment. Oxygen-deprived environments can be gener
`ated by storing the formulations under an inert gas such as, for
`example, nitrogen or argon. Liquid formulations are prefer
`ably stored at about 5° C.
`Ophthalmic LyophiliZed Formulations
`In one aspect of the invention, an ophthalmically accept
`able formulation comprising a VEGF antagonist is provided,
`Wherein the formulation is a lyophiliZable formulation. Lyo
`philiZable formulations can be reconstituted into solutions,
`suspensions, emulsions, or any other suitable form for admin
`istration or use. LyophiliZable formulations are typically ?rst
`prepared as liquids, then froZen and lyophiliZed. The total
`liquid volume before lyophiliZation can be less, equal to, or
`more than, the ?nal reconstituted volume of the lyophiliZed
`formulation. The lyophiliZation process is Well knoWn to
`
`Mylan Exhibit 1157
`Mylan v. Regeneron, IPR2021-00881
`Page 4
`
`

`

`7
`those of ordinary skill in the art, and typically includes sub
`limation of Water from a frozen formulation under controlled
`conditions.
`LyophiliZed formulations can be stored at a Wide range of
`temperatures. LyophiliZed formulations may be stored beloW
`25° C., for example, refrigerated at 2-8° C., or at room tem
`perature (e.g., approximately 25° C.). Preferably, lyophiliZed
`formulations are stored beloW about 25° C., more preferably,
`at about 4-20° C.; beloW about 40 C.; beloW about —20° C.;
`about —40° C.; about —70° C., or about —80° C. Stability of the
`lyophiliZed formulation may be determined in a number of
`Ways knoWn to the art, for example, by visual appearance of
`the cake and/or by moisture content.
`LyophiliZed formulations are typically reconstituted for
`use by addition of an aqueous solution to dissolve the lyo
`philiZed formulation. A Wide variety of aqueous solutions can
`be used to reconstitute a lyophiliZed formulation. Preferably,
`lyophiliZed formulations are reconstituted using Water. Lyo
`philiZed formulations are preferably reconstituted With a
`solution consisting essentially of Water (e.g., USP WFI, or
`Water for injection) or bacteriostatic Water (e.g., USP WFI
`With 0.9% benZyl alcohol). HoWever, solutions comprising
`buffers and/or excipients and/or one or more pharmaceuti
`cally acceptable carries can also be used.
`FreeZe-dried or lyophiliZed formulations are typically pre
`pared from liquids, that is, from solutions, suspensions, emul
`sions, and the like. Thus, the liquid that is to undergo freeZe
`drying or lyophiliZation preferably comprises all components
`desired in a ?nal reconstituted liquid formulation. As a result,
`When reconstituted, the freeZe-dried or lyophiliZed formula
`tion Will render a desired liquid formulation upon reconstitu
`tion.
`
`EXAMPLES
`
`Before the present methods are described, it is to be under
`stood that this invention is not limited to particular methods,
`and experimental conditions described, as such methods and
`conditions may vary. It is also to be understood that the
`terminology used herein is for the purpose of describing
`particular embodiments only, and is not intended to be limit
`ing, since the scope of the present invention Will be limited
`only to the appended claims.
`As used in this speci?cation and the appended claims, the
`singular forms “a”, “an”, and “the” include plural references
`unless the context clearly dictates otherWise. Thus for
`example, a reference to “a method” includes one or more
`methods, and/or steps of the type described herein and/or
`Which Will become apparent to those persons skilled in the art
`upon reading this disclosure and so forth.
`Unless de?ned otherWise, all technical and scienti?c terms
`used herein have the same meaning as commonly understood
`by one of ordinary skill in the art to Which this invention
`belongs. Although any methods and materials similar or
`equivalent to those described herein can be used in the prac
`tice or testing of the present invention, the preferred methods
`and materials are noW described. All publications mentioned
`herein are incorporated herein by reference in their entirety.
`
`Example 1
`
`Stability of 50 mg/ml VEGF Trap Liquid
`Formulation Stored at 5° C. in 3 ml Glass Vials
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`An ophthalmic liquid formulation containing 50 mg/ml
`65
`VEGF Trap (SEQ ID NO:4), 10 mM phosphate, 50 mM
`NaCl, 0.1% polysorbate 20, 5% sucrose, and pH 6.25, Was
`
`US 7,608,261 B2
`
`8
`stored at 5° C. in 3 ml glass vials and samples tested at 3, 6, 9,
`12, 18 and 24 months. Stability Was determined by SE-HPLC.
`The results are shoWn in Table 1. Turbidity Was measured at
`OD405 nm; and percent recovered protein and purity by siZe
`exclusion HPLC.
`
`5
`
`TABLE 1
`
`Stability of50 mg/ml VEGF Trap Protein (VGFT-SSO65)
`
`%
`VEGF Trap
`Turbidity
`Visual
`Months Appearance (OD405 nm) pH Recovered
`
`% VEGF Trap
`Native
`Con?guration
`
`0
`
`3
`
`6
`
`9
`
`12
`
`18
`
`24
`
`Pass
`
`Pass
`
`Pass
`
`Pass
`
`Pass
`
`Pass
`
`Pass
`
`0.00
`
`0.00
`
`0.01
`
`0.01
`
`0.01
`
`0.01
`
`0.01
`
`6.2
`
`6.2
`
`6.3
`
`6.3
`
`6.3
`
`6.3
`
`6.3
`
`100
`
`101
`
`100
`
`101
`
`104
`
`96
`
`105
`
`98.8
`
`98.7
`
`98.3
`
`98.3
`
`98.4
`
`98.1
`
`98.1
`
`Example 2
`
`Stability of 50 mg/ml VEGF Trap Liquid
`Formulation Stored at 5° C. in 3 ml Glass Vials
`
`A liquid formulation containing 50 mg/ml VEGF Trap
`(SEQ ID NO:4), 10 mM phosphate, 50 mM NaCl, 3% poly
`ethylene glycol 3350, 5% sucrose, and pH 6.25, Was stored at
`5° C. in 3 ml glass vials and samples tested at 3, 6, 9, 12, 18
`and 24 months. Stability results are shoWn in Table 2. Turbid
`ity, percent recovered protein and purity Was determined as
`described above.
`
`TABLE 2
`
`Stability of50 mg/ml VEGF Trap Protein (VGFT-SSO65)
`
`Visual
`Months Appearance Turbidity pH
`
`% VEGF Trap
`Recovered
`
`% VEGF Trap
`Native
`Con?guration
`
`0
`3
`6
`9
`12
`18
`24
`
`Pass
`Pass
`Pass
`Pass
`Pass
`Pass
`Pass
`
`0.00
`0.00
`0.01
`0.00
`0.01
`0.00
`0.00
`
`6.2
`6.1
`6.3
`6.3
`6.3
`6.3
`6.2
`
`100
`104
`99
`102
`103
`113
`106
`
`98.9
`98.5
`98.3
`97.6
`98.0
`97.7
`97.6
`
`Example 3
`
`Stability of 40 mg/ml VEGF Trap Liquid
`Formulation Stored at 5° C. in 3 ml Glass Vials
`
`A liquid formulation containing 40 mg/ml VEGF Trap
`(SEQ ID NO:4), 10 mM phosphate, 40 mM NaCl, 0.03%
`polysorbate 20, 5% sucrose, and pH 6.3, Was stored at 5° C. in
`3 ml glass vials and samples tested at 0.5, 1, 2, 3, and 4
`months. Stability results are shoWn in Table 3. Turbidity,
`percent recovered protein and purity Was determined as
`described above.
`
`Mylan Exhibit 1157
`Mylan v. Regeneron, IPR2021-00881
`Page 5
`
`

`

`US 7,608,261 B2
`
`10
`
`TABLE 3
`
`TABLE 5-continued
`
`Stability of 40 rng/rnl VEGF Trap Protein (V GFT-SS207)
`
`Visual
`Months Appearance Turbidity pH
`
`% VEGF Trap
`Recovered
`
`% VEGF Trap
`Native
`Con?guration
`
`0
`0.5
`1
`2
`3
`4
`
`Pass
`Pass
`Pass
`Pass
`Pass
`Pass
`
`0.00
`0.00
`0.00
`0.00
`0.01
`0.01
`
`6.3
`6.3
`6.2
`6.2
`6.4
`6.3
`
`100
`99
`98
`95
`
`99.5
`99.4
`99.5
`99.2
`
`Stability of40 rng/rnl VEGF Trap Protein (VGFT-SS203)
`
`Visual
`Months Appearance Turbidity pH
`
`% VEGF Trap
`Recovered
`
`Native
`Con?guration
`
`% VEGF Trap
`
`4
`
`5
`
`Pass
`
`Pass
`
`0.00
`
`0.00
`
`6.2
`
`6.3
`
`85
`
`84
`
`98.9
`
`99.0
`
`Example 4
`
`Stability of 40 mg/ml VEGF Trap Liquid
`Formulation Stored at 5° C. in Pre-Filled Glass
`Syringe
`
`A liquid formulation containing 40 mg/ml VEGF trap
`(SEQ ID NO:4), 10 mM phosphate, 40 mM NaCl, 0.03%
`polysorbate 20, 5% sucrose, and pH 6.3, Was stored at 5° C. in
`1 ml pre?lled luer glass syringe With 4023/50 FLUROTECTM
`coated (elastomer coated) plunger and samples tested at 0.5,
`1, 2, 3, and 4 months. Stability results are shoWn in Table 4.
`Turbidity, percent recovered protein and purity Was deter
`mined as described above.
`
`TABLE 4
`
`Example 6
`
`Stability of 40 mg/ml VEGF Trap Liquid
`Formulation Stored at 5° C. in 1 ml Pre-Filled Glass
`Syringe
`
`25
`
`30
`
`A liquid formulation containing 40 mg/ml VEGF trap
`(SEQ ID NO:4), 10 mM phosphate, 135 mM NaCl, 0.03%
`polysorbate 20, and pH 6.3, Was stored at 5° C. in 1 ml
`pre?lled glass luer syringe With 4023/50 FLUROTECTM
`coated (elastomer coated) plunger and samples tested at 0.5,
`1, 2, 3, 4, and 5 months. Stability results are shoWn in Table 6.
`Turbidity, percent recovered protein and purity Was deter
`mined as described above.
`
`Stability of 40 rng/rnl VEGF Trap Protein (V GFT-SS207)
`
`Visual
`Months Appearance Turbidity pH
`
`% VEGF Trap
`Recovered
`
`% VEGF Trap
`Native
`Con?guration
`
`35
`
`0
`0.5
`1
`2
`3
`4
`
`Pass
`Pass
`Pass
`Pass
`Pass
`Pass
`
`0.00
`0.00
`0.00
`0.00
`0.01
`0.01
`
`6.3
`6.3
`6.3
`6.3
`6.4
`6.3
`
`100
`100
`100
`97
`
`99.4
`99.3
`99.4
`99.1
`
`Example 5
`
`Stability of 40 mg/ml VEGF Trap Liquid
`Formulation Stored at 5° C. in 3 ml Glass Vials
`
`TABLE 6
`
`Stability of40 rng/rnl VEGF Trap Protein (VGFT-SS203)
`
`Visual
`Months Appearance Turbidity pH
`
`% VEGF Trap
`Recovered
`
`% VEGF Trap
`Native
`Con?guration
`
`40
`
`45
`
`0
`0.5
`1
`
`2
`
`3
`4
`5
`
`Pass
`Pass
`Pass
`
`Pass
`
`Pass
`Pass
`Pass
`
`0.00
`0.01
`0.00
`
`0.00
`
`0.01
`0.01
`0.00
`
`6.3
`6.3
`6.3
`
`6.3
`
`6.3
`6.3
`6.3
`
`100
`101
`101
`
`i
`
`102
`103
`99
`
`99.2
`99.2
`99.2
`
`i
`
`99.1
`98.8
`98.9
`
`A liquid formulation containing 40 mg/ml VEGF trap
`(SEQ ID NO:4), 10 mM phosphate, 135 mM NaCl, 0.03%
`polysorbate 20, and pH 6.3, Was stored at 5° C. in 3 ml glass
`vials and samples tested at 0.5, 1, 2, 3, and 4 months. Stability
`results are shoWn in Table 5. Turbidity, percent recovered
`protein and purity Was determined as described above.
`
`50
`
`55
`
`Example 7
`
`Stability of LyophiliZed 20 mg/ml VEGF Trap
`Formulation Stored at 5° C. in 3 ml Glass Vials and
`Reconstituted to 40 mg/ml
`
`TABLE 5
`
`Stability of 40 rng/rnl VEGF Trap Protein (V GFT-SS203)
`
`Visual
`Months Appearance Turbidity pH
`
`% VEGF Trap
`Recovered
`
`0
`0.5
`1
`2
`3
`
`Pass
`Pass
`Pass
`Pass
`Pass
`
`0.00
`0.00
`0.00
`0.00
`0.00
`
`6.3
`6.2
`6.2
`6.3
`6.3
`
`100
`87
`88
`103
`88
`
`60
`
`% VEGF Trap
`Native
`Con?guration
`
`99.3
`99.2
`99.1
`99.2
`99.0
`
`65
`
`0.8 ml of a liquid formulation containing 20 mg/ml VEGF
`trap (SEQ ID NO:4), 5 mM phosphate, 20 mM NaCl, 0.015%
`polysorbate 20, 2.5% sucrose, andpH 6.3, Were lyophiliZed in
`3 ml glass vials. Samples Were stored at 5° C. and tested at 1,
`and 2 months. VEGF trap Was reconstituted to a ?nal concen
`tration of 40 mg/ml VEGF Trap (?nal volume of 0.4 ml).
`Stability results are shoWn in Table 7 (t?ime in months;
`*q/isual appearance; **:reconstitution time). Turbidity, per
`cent recovered protein and purity Was determined as
`described above.
`
`Mylan Exhibit 1157
`Mylan v. Regeneron, IPR2021-00881
`Page 6
`
`

`

`11
`
`12
`
`US 7,608,261 B2
`
`TABLE 7
`of Lyophilized 20 mg/ml VEGF Tra

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket